Jennison Associates LLC Arvinas, Inc. Transaction History

Jennison Associates LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 02, 2022	SELL	$36.01 - $74.24 $8.6 Million - $17.7 Million	-238,774 Closed	0 $0
Q1 2022 May 11, 2022	SELL	$60.27 - $81.57 $95,829 - $129,696	-1,590 Reduced 0.66%	238,774 $16.1 Million
Q4 2021 Feb 08, 2022	BUY	$65.85 - $96.21 $5.19 Million - $7.58 Million	78,780 Added 48.75%	240,364 $19.7 Million
Q3 2021 Nov 09, 2021	SELL	$73.2 - $107.87 $150,133 - $221,241	-2,051 Reduced 1.25%	161,584 $13.3 Million
Q1 2021 May 11, 2021	BUY	$58.19 - $91.37 $4.46 Million - $7 Million	76,635 Added 88.09%	163,635 $10.8 Million
Q4 2020 Feb 05, 2021	BUY	$20.19 - $84.93 $1.76 Million - $7.39 Million	87,000 New	87,000 $7.39 Million

224

70.9M

1.52M

346K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $986M
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Jennison Associates LLC, based on Form 13F filings with the SEC.

Stay updated on Jennison Associates LLC with notifications on news.